Trastuzumab deruxtecan (DS-8201a; fam-trastuzumab deruxtecan; Enhertu) is a novel, potent and next-generation antibody-drug conjugate (ADC) composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, an exatecan derivative (DX-8951f). It is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. DS-8201a resulted in favorable outcomes in HER2-positive heavily pretreated breast cancer patients and also had a promising efficacy in patients with HER2-negative/low-expressing disease.

纯度：≥98%

CAS：1826843-81-5